Medicinal plants containing cardiac glycosides were known to the ancient Egyptians 3000 years ago, but these agents were used randomly and with variable success until the 18th century, when William Withering an English physician and botanist, published a monograph describing the clinical effects of an extract of the foxglove plant i.e., Digitalis purpurea in 1785, described in detail the indication for use of cardiacglycoside. Digitoxin is a cardiac glycoside obtained from Digitalis purpurea and other suitable species of of Digitalis, containing 3 molecules of digitxose linked to digitoxigenin. It has both lipophilic (steroid nucleus) and hydrophilic (lactone ring, hydroxyl, sugar) groups. It makes the heart function more efficient. It increases the force of contraction of heart and slows heart rate, used to treat congestive heart failure, to control ventricular rate in the treatment of supraventricular dysrhythmias including atrial fibrillation and flutter, and to treat paroxysmal atrial tachycardia. Digitoxin is administered orally, intramuscularly or intravenously.